{
  "trial_id": "NCT00887146",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "United States (US) and Canadian sites",
      "label": "met"
    },
    {
      "criterion": "This review is mandatory prior to registration to confirm eligibility; patients must be willing to submit tissue samples for mandatory central pathology review submission;",
      "label": "unknown"
    },
    {
      "criterion": "Tissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review",
      "label": "met"
    },
    {
      "criterion": "Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility, the 1p/19q analysis results will be accepted from the local site, as determined by either a locally available or reference laboratory (for US, must be Clinical Laboratory Improvement Act [CLIA] certified); acceptable methods for determination of 1p/19q loss include fluorescent in-situ hybridization (FISH), by genomic sequencing or methylomic analyses;",
      "label": "met"
    },
    {
      "criterion": "Tumor must also show evidence of IDH mutation by immunohistochemistry or genomic analyses; this should be performed at the local site (US: performed in a CLIA certified laboratory);",
      "label": "unknown"
    },
    {
      "criterion": "Newly diagnosed and =< 3 months from surgical diagnosis;",
      "label": "met"
    },
    {
      "criterion": "Histological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p/19q loss and the presence of an either IDH1 or IDH2, both as established by a local or referenced laboratory qualified for the study;",
      "label": "met"
    },
    {
      "criterion": "Patients with codeleted low grade gliomas must also be considered \"high risk\" by exhibiting one or more of the following characteristics: Age >= 40 and any surgical therapy;",
      "label": "unknown"
    },
    {
      "criterion": "Absolute neutrophil count (ANC) >= 1,500/mm^3 obtained =< 21 days prior to registration;",
      "label": "met"
    },
    {
      "criterion": "Platelet (PLTs) count >= 100,000/mm^3 obtained =< 21 days prior to registration;",
      "label": "unknown"
    },
    {
      "criterion": "Hemoglobin (Hgb) > 9.0 g/dL obtained =< 21 days prior to registration;",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant women",
      "label": "not_met"
    },
    {
      "criterion": "Nursing women",
      "label": "not_met"
    },
    {
      "criterion": "Men or women of childbearing potential who are unwilling to employ adequate contraception or contraceptive method during this study and 6 months following the completion of chemotherapy treatments;",
      "label": "unknown"
    }
  ],
  "notes": "Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00887146",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}